Determination of the economically justifiable price of cenobamate in the treatment of focal-onset seizures in adult patients with drug-resistant epilepsy in Spain.

Miguel Ángel Ma Calleja-HernándezAndrés NavarroJosé María SerratosaManuel ToledoVicente VillanuevaSilvia Subías LabazuyAlicia Gil

Published in: Expert review of pharmacoeconomics & outcomes research (2022)

Treatment with cenobamate produces incremental clinical benefit over third-generation ASMs, and at the base-case, EJP could represent a cost-effective option for the adjunctive treatment of FOS in adult patients with DRE in Spain.

Keyphrases

drug resistant
multidrug resistant
combination therapy
mass spectrometry
high resolution
liquid chromatography